ProductsPricingFree Market DashboardMarket News FeedScannerChartsHeatmapMarket SectorsTrack RecordMAD AcademyMCP Connector

Spyre Therapeutics, Inc. (SYRE)

Nasdaq · Common stock · Pharmaceutical Preparations

$93.40+2.00 (+2.19%)

As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.

Follow SYRE in real time

Real-time quotes, Pro Charting, the scanner and the alert feed on SYRE and every other US listing.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Or open the free SYRE chart →

SYRE at a glance

Key statistics

$8.54B

Market capitalization

Previous close
$91.40
Open
$92.81
Day range
$92.34 – $95.04
Volume
445.5K
Average volume (30 sessions)
1.47M
Shares outstanding
101.91M
Earnings per share
$(1.61)
Price / book
7.8
Beta (1 year, vs SPY)
1.81

Where the price sits in its year

52-week range

81% of the range

Below the 52-week high
-15.2%
Above the 52-week low
+341.7%

Completed sessions through Oct 20, 2026

Technical snapshot

Below its 50-day average, above its 200-day

20-day average
$85.20+7.3%
50-day average
$91.63-0.3%
200-day average
$70.66+29.4%
RSI (14)56.6

Between the conventional 30 and 70 bands.

+13.6%

1 week

-0.7%

1 month

-7.8%

3 months

+179.0%

Year to date

+306.8%

1 year

Price change over each window, from completed sessions. Past performance does not indicate future results.

Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.

The member platform, in real time

What members do with SYRE

Every plan

SYRE on Pro Charting

Every intraday interval in real time, the drawing kit and the full set of technical studies on SYRE.

See the plans →

Every plan

Screen names like SYRE

The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.

See the plans →

Analysis Tools Only

Set a price line on SYRE

Put SYRE on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.

See the plans →

Stock Alerts + Tools

Open alerts on SYRE

See whether there is an open premium alert on SYRE, with its entry, stop and exit, each one reviewed by an analyst before it is sent.

See the plans →

From the public news wire

SYRE headlines

Market news →

SEC Form 4, most recent first

Insider filings

How to read these →

  • Burrows Scott L

    −3.1K

    Chief Financial Officer · Open-market sale

    $285.45K · Oct 1, 2026

  • Turtle Cameron

    −600

    Chief Executive Officer, Director · Open-market sale

    $53.48K · Oct 1, 2026

  • Turtle Cameron

    −4.0K

    Chief Executive Officer, Director · Open-market sale

    $368.22K · Oct 1, 2026

  • King-Jones Heidy

    −7.2K

    See Remarks · Open-market sale

    $660.28K · Oct 1, 2026

  • Burrows Scott L

    −2.1K

    Chief Financial Officer · Open-market sale

    $193.03K · Oct 1, 2026

  • King-Jones Heidy

    −400

    See Remarks · Open-market sale

    $35.70K · Oct 1, 2026

  • Burrows Scott L

    −1.5K

    Chief Financial Officer · Open-market sale

    $135.41K · Oct 1, 2026

  • King-Jones Heidy

    −16.6K

    See Remarks · Open-market sale

    $1.50M · Oct 1, 2026

About Spyre Therapeutics, Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Exchange
Nasdaq
Security
Common stock
Industry
Pharmaceutical Preparations
Headquarters
Waltham, MA
Employees
112
Listed since
Apr 7, 2016
Website
spyre.com
Educational content only. MadStockAlerts provides market commentary, research, and educational content. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security. Trading and investing involve substantial risk, including loss of capital. See the Risk Disclosure and Customer Agreement.

Pick the desk that fits how you trade

Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.